Active Ingredient History
Fostamatinib is a pro-drug of a Syk inhibitor R406 initially developed by Rigel Pharmaceuticals, but then in-licensed by AstraZeneca. It reached phase III of clinical trials for such diseases as Rheumatoid Arthritis and Immune Thrombocytopenic Purpura, however, AstraZeneca decided not to proceed with regulatory filings and return the rights to the compound to Rigel Pharmaceuticals. In 2018 the drug was approved by the FDA for treatment of chronic immune thrombocytopenia. Fostamatinib is being developed for Autoimmune Hemolytic Anemia (phase II), graft versus host disease (phase I) and ovarian cancer (phase I). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Purpura, Thrombocytopenic, Idiopathic (approved 2018)
Anemia, Hemolytic, Autoimmune (Phase 2)
Arthritis, Rheumatoid (Phase 3)
Biological Availability (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Colorectal Neoplasms (Phase 2)
Coronavirus (Phase 1/Phase 2)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 3)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 1)
Glomerulonephritis, IGA (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 1)
Hidradenitis Suppurativa (Phase 2)
Kidney Failure, Chronic (Phase 1)
Kidney Transplantation (Phase 1/Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liver Diseases (Phase 1)
Lupus Erythematosus, Systemic (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, T-Cell (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Ovarian Neoplasms (Phase 1)
Pharmacokinetics (Phase 1)
Pheochromocytoma (Phase 2)
Pioglitazone (Phase 1)
Pneumonia (Phase 3)
Pneumonia, Viral (Phase 3)
Primary Myelofibrosis (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 3)
Severe Acute Respiratory Syndrome (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
